Envestnet Portfolio Solutions Inc. Grows Position in DexCom, Inc. (NASDAQ:DXCM)

Envestnet Portfolio Solutions Inc. grew its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 30.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,159 shares of the medical device company's stock after purchasing an additional 3,778 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in DexCom were worth $1,257,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Blue Whale Capital LLP increased its holdings in shares of DexCom by 91.9% in the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock worth $15,821,000 after acquiring an additional 113,000 shares during the period. Motley Fool Asset Management LLC grew its position in DexCom by 168.7% in the 3rd quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company's stock worth $17,993,000 after purchasing an additional 171,150 shares during the last quarter. Watts Gwilliam & Co. LLC acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $3,334,000. Congress Asset Management Co. raised its holdings in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after buying an additional 1,332,522 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in shares of DexCom by 2,226.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock worth $18,085,000 after buying an additional 222,548 shares during the period. Institutional investors own 97.75% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several analysts have weighed in on DXCM shares. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Canaccord Genuity Group upped their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Morgan Stanley raised their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and boosted their price target for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Cfra Research raised DexCom to a "hold" rating in a report on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, DexCom currently has an average rating of "Moderate Buy" and an average target price of $99.82.

DexCom Price Performance

DXCM traded down $1.42 on Wednesday, reaching $72.13. The company had a trading volume of 3,270,273 shares, compared to its average volume of 3,909,139. The company has a market cap of $28.19 billion, a price-to-earnings ratio of 50.44, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The business has a 50 day simple moving average of $83.13 and a 200 day simple moving average of $77.11.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares in the company, valued at $26,183,401.02. The trade was a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.